Research Scientist Position in Functional Cancer Genomics

The Functional Cancer Genomics group directed by Prof. J.P. Theurillat at the Institute of Oncology Research in Bellinzona, Switzerland ( is seeking a Research Scientist.

The successful candidate will work as part of an international team that is dedicated to understanding how new driver alterations culled from cancer genome characterization studies promote tumorigenesis, and how gathered insights can be exploited to develop precision medicines. The position offers excellent scientific opportunities in a highly stimulating and interdisciplinary environment involving close interactions between medical and basic scientists. Investigations range from projects related to:

  • Functional characterization of new prostate cancer drivers implicated in chromatin remodeling
  • Engineering of small molecules against key targets of lethal prostate cancer

Candidate requirements

  • Determined to solve important and challenging questions in biology/medicine
  • Ph.D or M.D./Ph.D. (already obtained or soon-to-be)
  • At least one first author publication
  • Strong background in chromatin biology and ChIP sequencing

The position is located at the Institute of Oncology Research, a leading institution in basic and translational cancer research in Southern Switzerland with state-of-the-art core facilities and competitive salaries. The highly collaborative lab has ongoing projects with groups at Harvard, MIT and ETHZ, among others.

Starting date spring to summer 2018

For inquiry regarding this job or submission of complete application including two references please contact Prof. Jean-Philippe Theurillat via email:

Selected recent publications:

-Janouskova H, et al. Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors. Nat Med, 2017. PMID: 28805821

-Groner A, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell, 2016 PMID: 27238081

-Theurillat JP, et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science, 2014 PMID: 25278611

-Whittaker SR, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov, 2013 PMID: 23288408

-Barbieri CE1, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet, 2012 PMID: 22610119

-Theurillat JP, et al. URI is an oncogene amplified in ovarian cancer cells and is required for their

survival. Cancer Cell, 2011 PMID: 21397856